transmembrane protein 91Genealiases: DSPC3 · IFITMD6 · SynDIG3
Q-omics provides the consensus-scored TMEM91 profile across patient tissues and cancer cell-line models. TMEM91 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM91 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMEM91 RNA expression shows 17,541 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where TMEM91 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM91 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM91 survival associations across molecular data types. TMEM91 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM91 RNA expression–survival associations across cancer types. High TMEM91 expression shows unfavorable associations in ACC, OV, KIRP, LIHC and UCS, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM91 RNA expression.
This table summarizes TMEM91 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM91. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM91 shows lower tumor expression in KICH, BRCA and LUAD and higher tumor expression in KIRC, CHOL and LIHC. The KIRC box plot shows higher TMEM91 RNA expression in tumor versus normal tissue (log2 FC = +3.131, t-test p < 0.001).
This table shows molecular features associated with TMEM91 in patient tissues and cancer cell lines. In patient samples, TMEM91 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM91 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
